Schoellnast Helmut, Deodhar Ajita, Hsu Meier, Moskowitz Chaya, Nehmeh Sadek A, Thornton Raymond H, Sofocleous Constantinos T, Alago William, Downey Robert J, Azzoli Christopher G, Rosenzweig Kenneth E, Solomon Stephen B
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Acta Radiol. 2012 Oct 1;53(8):893-9. doi: 10.1258/ar.2012.110333. Epub 2012 Sep 7.
Radiofrequency ablation (RFA) is a potential application as a salvage tool after failure of surgery, chemotherapy, or radiotherapy of non-small cell lung cancer (NSCLC). Although several studies have evaluated the use of RFA in primary NSCLC, there is little literature on its potential application as a salvage tool.
To evaluate CT-guided RFA employed as a salvage therapy for pulmonary recurrences of NSCLC after prior treatment with chemotherapy, radiation therapy, and/or surgery.
A retrospective computer database search yielded 33 patients with biopsy proven primary NSCLC who underwent CT-guided RFA of 39 recurrent tumors following surgery, chemotherapy, and/or radiotherapy. Follow-up imaging was performed with CT and PET-CT. The endpoints of interest were progression-free survival (PFS) and time to local progression (TTLP). PFS and TTLP were compared by lesion size (<3 cm, ≥3 cm).
The median PFS was 8 months. For patients with a tumor size <3 cm median PFS was 11 months, whereas the median PFS of patients with a tumor size ≥3 cm was 5 months. The difference did not reach statistical significance (P = 0.09). The median TTLP of all tumors was 14 months. TTLP of ablated tumors <3 cm in size was 24 months, compared to 8 months for ablated tumors ≥3 cm in size. The difference did not reach statistical significance (P = 0.07).
RFA of recurrent NSCLC may be a valuable salvage tool to achieve local tumor control, especially in tumors measuring <3 cm in size.
射频消融(RFA)作为非小细胞肺癌(NSCLC)手术、化疗或放疗失败后的挽救性治疗手段具有潜在应用价值。尽管已有多项研究评估了RFA在原发性NSCLC中的应用,但关于其作为挽救性治疗手段的潜在应用的文献较少。
评估CT引导下的RFA作为NSCLC经化疗、放疗和/或手术治疗后肺部复发的挽救性治疗方法。
通过回顾性计算机数据库检索,筛选出33例经活检证实为原发性NSCLC的患者,这些患者在手术、化疗和/或放疗后对39个复发性肿瘤进行了CT引导下的RFA治疗。采用CT和PET-CT进行随访成像。观察终点为无进展生存期(PFS)和局部进展时间(TTLP)。根据肿瘤大小(<3 cm,≥3 cm)比较PFS和TTLP。
中位PFS为8个月。肿瘤大小<3 cm的患者中位PFS为11个月,而肿瘤大小≥3 cm的患者中位PFS为5个月。差异未达到统计学意义(P = 0.09)。所有肿瘤的中位TTLP为14个月。大小<3 cm的消融肿瘤的TTLP为24个月,而大小≥3 cm的消融肿瘤的TTLP为8个月。差异未达到统计学意义(P = 0.07)。
复发性NSCLC的RFA可能是实现局部肿瘤控制的一种有价值的挽救性治疗手段,尤其是对于大小<3 cm的肿瘤。